36 results on '"Junge, Candice"'
Search Results
2. Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
3. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
4. ATXN7-Related Cone-Rod Dystrophy
5. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
6. Butyrylcholinesterase Kalow variant reduces age‐of‐onset of Alzheimer Disease in apolipoprotein ɛ4 carriers
7. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease
8. Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
9. The Contribution of Protease-Activated Receptor 1 to Neuronal Damage Caused by Transient Focal Cerebral Ischemia
10. Pelizaeus-Merzbacher Disease: A Caregiver Assessment of Disease Impact
11. The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34+ Cell Administration in Patients With Refractory Angina
12. sj-pdf-2-jcn-10.1177_08830738231152658 - Supplemental material for Pelizaeus-Merzbacher Disease: A Caregiver Assessment of Disease Impact
13. sj-docx-1-jcn-10.1177_08830738231152658 - Supplemental material for Pelizaeus-Merzbacher Disease: A Caregiver Assessment of Disease Impact
14. PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI
15. Tau-targeting antisense oligonucleotide MAPTRxin mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
16. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: Design of the RENEW study
17. Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes
18. Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: An analysis from ACT34-CMI
19. Activation of protease activated receptor 1 increases the excitability of the dentate granule neurons of hippocampus
20. Author Correction: Tau-targeting antisense oligonucleotide MAPTRxin mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
21. PreSERVE-AMI
22. Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study
23. The RENEW Trial
24. Abstract 12754: Infused CD34 Cell Dose, not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients With Left Ventricular Dysfunction post STEMI: Results of the PreSERVE-AMI Trial
25. ONE YEAR FOLLOW-UP RESULTS FROM PRESERVE-AMI: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF INTRACORONARY INFUSION OF AUTOLOGOUS CD34+ CELLS IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION POST STEMI
26. Results of the first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with...
27. Abstract 1274: SLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancers.
28. IMPACT OF MOBILIZATION ABILITY ON CELL FUNCTIONALITY AND COMPARISON OF NORMAL AND CMI SUBJECT SAMPLES: AN ANALYSIS FROM ACT34–CMI
29. ELECTROMECHANICAL ASSESSMENT OF MYOCARDIAL FUNCTION (NOGA) IS ASSOCIATED WITH EXERCISE IMPROVEMENT IN PATIENTS TREATED WITH AUTOLOGOUS STEM CELL THERAPY FOR REFRACTORY ANGINA
30. Autologous CD34+Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study
31. The Serine Protease Plasmin Cleaves the Amino-terminal Domain of the NR2A Subunit to Relieve Zinc Inhibition of the N-Methyl-d-aspartate Receptors
32. Plasmin Potentiates Synaptic N-Methyl-D-aspartate Receptor Function in Hippocampal Neurons through Activation of Protease-activated Receptor-1
33. Potentiation of NMDA Receptor Function by the Serine Protease Thrombin
34. A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia.
35. The Serine Protease Plasm in Cleaves the Amino-terminal Domain of the NR2A Subunit to Relieve Zinc Inhibition of the N-Methyl-D-aspartate Receptors.
36. Autologous CD34 + Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.